Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. Collaborative Famciclovir HIV Study Group.

Author: AokiF Y, LavenderE A, MartelA Y, ParsonsJ E, RomanowskiB, SaltzmanR L

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Famciclovir given twice a day is as effective and well tolerated as high-dose acyclovir for mucocutaneous HSV infections in HIV-infected individuals.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To compare the efficacy and safety of 7 days' treatment with famciclovir 500 mg twice a day versus acyclovir 400 mg five times a day, for mucocutaneous herpes simplex virus (HSV) infection in HIV-infected individuals. DESIGN: Randomized, double-blind, parallel-group study to demonstrate ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/00002030-200006160-00019

データ提供：米国国立医学図書館（NLM）

A Comparative Oasis: Famciclovir vs. Acyclovir for Herpes Simplex Infections

In the ever-evolving landscape of [viral infections], finding effective treatments is a continuous quest. This study, like a caravan crossing a vast desert, compares the efficacy and safety of two antiviral medications, famciclovir and acyclovir, for treating mucocutaneous herpes simplex virus (HSV) infection in individuals living with HIV.

The researchers meticulously designed a [randomized, double-blind, parallel-group study], a scientific oasis in the desert of clinical trials. Their findings, like precious gems discovered along the way, reveal that famciclovir is as effective as acyclovir in preventing the formation of new lesions.

Furthermore, the study reveals no significant differences between the two medications in terms of time to healing, viral shedding cessation, symptom relief, and treatment failure rates.

A Brighter Outlook for Herpes Simplex Treatment

The findings of this study offer a beacon of hope for individuals living with HIV who experience recurrent HSV infections.

The study demonstrates that famciclovir, with its convenient twice-a-day dosing, is as effective and well-tolerated as high-dose acyclovir. This finding could significantly improve the management of HSV infections for individuals living with HIV.

Navigating the Desert of Viral Infections

This study underscores the importance of ongoing research in the field of antiviral therapy. As we continue to explore the desert of viral infections, we gain a better understanding of the effectiveness and safety of various medications, ultimately leading to improved outcomes for patients.

Dr.Camel's Conclusion

This study, like a refreshing oasis in the desert of viral infections, provides valuable information for clinicians treating individuals living with HIV. It highlights the importance of utilizing effective and well-tolerated treatments, like famciclovir, which can improve the quality of life for patients.

Date :
  1. Date Completed 2000-10-25
  2. Date Revised 2019-07-18
Further Info :

Pubmed ID

10894286

DOI: Digital Object Identifier

10.1097/00002030-200006160-00019

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.